TrialBreast cancer (Tokyo, Japan)2026

Prognosis of ER-positive, HER2-negative postmenopausal early breast cancer patients based on response to neoadjuvant endocrine therapy and multigene assay results: findings from the NEOS trial.

Hiroji Iwata et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.